Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 7,323 | 9,954 | 9,178 | 6,599 | 10,056 |
Gross Profit | 7,323 | 9,954 | 9,178 | 6,599 | 10,056 |
Operating Expenses | 100,777 | 64,848 | 75,232 | 61,489 | 61,445 |
Operating Income | -93,454 | -54,894 | -66,054 | -54,890 | -51,389 |
Other Income | 45,267 | 12,147 | 17,453 | 15,614 | 13,385 |
Pre-tax Income | -48,187 | -42,747 | -48,601 | -39,276 | -38,004 |
Income Tax | -11,257 | -2,137 | -1,451 | -10,666 | -7,476 |
Net Income Continuous | -36,930 | -40,610 | -47,150 | -28,610 | -30,528 |
Net Income | $-36,930 | $-40,610 | $-47,150 | $-28,610 | $-30,528 |
EPS Basic Total Ops | -0.13 | -0.14 | -0.16 | -0.10 | -0.11 |
EPS Basic Continuous Ops | -0.13 | -0.14 | -0.16 | -0.10 | -0.11 |
EPS Diluted Total Ops | -0.13 | -0.14 | -0.16 | -0.10 | -0.11 |
EPS Diluted Continuous Ops | -0.13 | -0.14 | -0.16 | -0.10 | -0.11 |
EPS Diluted Before Non-Recurring Items | -0.13 | -0.14 | -0.17 | -0.10 | -0.11 |
EBITDA(a) | $-55,417 | $-48,128 | $-56,945 | $-47,481 | $-44,133 |